Go Back
Imcyse
Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases.
More Details
The company’s unique technology platform has the potential to address a wide range of indications in the vast field of immunology with active development programs ongoing in T1D, multiple sclerosis, rheumatoid arthritis, neuromyelitis optica and celiac disease.
The technology is based on the administration of modified synthetic peptides – ImotopesTM, which specifically block improper immune responses. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense.